Lyell Immunopharma Cash Flow Statement (2020-2026) | LYEL

Cash Flow Statement Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Operating Activities
Net Income (Quarter)
-60.65M-176.32M-175.37M-129.98M-188.38M-13.56M-83.31M-90.81M-70.05M-306.84M-74.91M-129.48M-124.41M-561.06M-128.88M-115.47M-102.17M-144.69M-103.22M-102.94M
Share-based Compensation (Quarter)
13.04M22.03M-22.03M0.37M81.56M13.88M-13.76M38.50M8.46M9.15M8.28M7.62M8.08M6.02M5.00M5.23M25.57M4.29M4.53M
Gains from Investment Securities (Quarter)
0.04M36.40M5.00M-3.93M10.00M2.92M13.00M-13.00M
Asset Writedowns and Impairment (Quarter)
36.40M5.00M-5.00M51.30M1.40M-0.04M
Cash from Operations (Quarter)
-25.49M-33.21M-47.85M-44.33M-37.10M-40.27M-46.21M-39.16M-37.69M-40.63M-42.02M-38.09M-35.04M-47.24M-54.74M-34.46M-28.58M-32.25M-38.51M-33.92M
Depreciation, Depletion & Amortization
Amortizatization of Intangibles (Quarter)
-0.55M-0.47M-0.47M-0.23M0.43M1.21M1.85M2.08M2.29M3.38M4.37M3.76M3.59M2.96M1.73M1.17M1.01M1.06M0.89M0.82M
Depreciation & Amortization (CF) (Quarter)
4.09M4.57M4.19M4.17M4.62M5.04M5.03M5.06M5.10M5.06M5.02M4.90M4.68M5.03M3.44M3.13M2.57M2.40M2.33M2.22M
Change in Working Capital
Change in Account Payables (Quarter)
-0.99M0.10M2.94M-1.77M0.02M-0.53M2.07M0.38M-1.41M0.42M-0.11M-0.52M-0.57M-2.04M-1.65M-0.23M-0.78M0.33M2.38M-1.46M
Change in Accured Expenses (Quarter)
1.94M4.22M-6.39M-0.77M1.32M5.37M-5.86M2.27M4.61M-1.74M-3.61M0.52M3.09M-1.25M-9.79M-3.33M0.57M4.90M-3.57M4.61M
Other Working Capital Changes (Quarter)
-2.64M-2.81M-0.11M-0.11M3.56M-3.78M-0.11M-0.11M-0.11M-0.11M-0.11M-0.11M0.13M-0.31M-0.11M-0.11M-0.35M-2.16M0.01M0.01M
Investing Activities
Capital Expenditures (Quarter)
-1.15M60.07M0.11M3.45M16.14M-18.37M1.53M0.93M-2.46M2.68M0.03M0.02M0.37M-0.28M0.15M0.26M-0.41M0.78M0.09M0.15M
Sales of Property, Plant and Equipment (Quarter)
0.02M
Change in Acquisitions & Divestments (Quarter)
142.04M70.33M79.81M121.85M106.50M110.90M142.25M187.10M178.15M156.12M130.03M161.80M133.41M123.70M154.12M93.52M74.14M52.91M54.65M69.39M
Cash from Investing Activities (Quarter)
-144.91M-73.86M-26.12M25.02M-57.09M46.65M32.15M152.91M99.67M-100.69M21.99M45.01M1.92M53.51M69.47M12.65M3.35M-31.36M17.38M15.62M
Financing Activities
Other financing activities (Quarter)
0.53M389.76M2.56M1.57M-3.24M8.69M1.16M-1.01M0.15M0.10M0.71M-0.66M1.09M0.18M0.18M0.03M0.50M
Change in Capital Stock
Shares Issued (Quarter)
43.56M
Net Equity Issued and Repurchased (Quarter)
1.70M
Misc.
Cash from Financing Activities (Quarter)
-0.53M7.40M2.56M2.46M4.76M0.86M-0.07M1.20M-0.14M0.76M0.03M0.86M0.44M0.00M0.18M50.00M0.22M51.72M0.52M
Change in Cash (Quarter)
-170.94M-99.68M-71.42M-16.86M-89.43M7.24M-14.13M114.95M61.84M-140.57M-20.00M7.78M-33.12M6.70M14.73M-21.63M24.77M-63.39M30.59M-17.78M
Free Cash Flow (Quarter)
-24.34M-93.28M-47.96M-47.78M-53.24M-21.90M-47.74M-40.09M-35.22M-43.32M-42.05M-38.11M-35.41M-46.97M-54.89M-34.72M-28.16M-33.03M-38.60M-34.08M
Net Cash Flow (Quarter)
-170.94M-99.68M-71.42M-16.86M-89.43M7.24M-14.13M114.95M61.84M-140.57M-20.00M7.78M-33.12M6.70M14.73M-21.63M24.77M-63.39M30.59M-17.78M